OUR COMMITMENT TO THE COMMUNITY HAS A NEW LOOK

Your quarterly newsletter has the insights and information you want—with a whole new look.

Pfizer has been working to make people's lives healthier for more than 150 years. And Pfizer's commitment to the hemophilia community is one more great example. Get ready for a world of support, innovation, and resources.

What's in Hemophilia Village for you?

• Stories and videos from people in the hemophilia community
• Useful health and fitness tips
• Product and treatment information
• The latest events in your local chapters
• Essential downloadable resources
• Information about our scholarship program

Say hello to The Villager newsletter.

Our newsletter has been changed from top to bottom. It's now called The Villager, and has an exciting new look and focus. What will The Villager deliver? The stories, news, and information you told us were important to you. You'll find great ways to connect with the hemophilia community, through unique and exciting community updates. The Villager was created with the most important feedback of all, yours.

A village built around you.

In addition to The Villager  newsletter, you can look forward to exciting changes to HemophiliaVillage.com coming soon. We value your opinions and are now updating the site and offerings to make Hemophilia Village even more in line with your needs.

Looking forward.

Both The Villager  and HemophiliaVillage.com have the full commitment of Pfizer behind them. We think you'll find The Villager and Hemophilia Village an ideal way to stay connected to the community.

Coming soon: Updates to HemophiliaVillage.com.

What Is XYNTHA?

Xyntha® Antihemophilic Factor (Recombinant), Plasma/Albumin-Free is indicated for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.

XYNTHA does not contain von Willebrand factor and, therefore, is not indicated in von Willebrand's disease.

Important Safety Information for XYNTHA

• Allergic reactions are possible with XYNTHA. Signs of an allergic reaction may include hives, rash with itching, chest tightness, difficulty breathing, faintness, or fast heartbeat. XYNTHA contains trace amounts of hamster protein. You may develop an allergic reaction to these proteins. Tell your doctor if you have had an allergic reaction to hamster protein.
• Call your doctor right away if bleeding is not controlled after using your factor VIII replacement therapy; this may be a sign of an inhibitor. Inhibitors have been observed in patients receiving factor VIII products, including XYNTHA.
• The most common adverse reaction in study 1 (safety and efficacy study) is headache (24% of subjects) and in study 2 (surgery study) is fever (41% of subjects). Other common side effects of XYNTHA include nausea, vomiting, diarrhea, or weakness.
• XYNTHA is an injectable medicine administered by intravenous (IV) infusion. Local irritation may occur when infusing XYNTHA after reconstitution in XYNTHA Solofuse.

Please see full Prescribing Information for XYNTHA.

What Is BeneFIX?

BeneFIX® Coagulation Factor IX (Recombinant) is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease.

BeneFIX is NOT used to treat hemophilia A.

Important Safety Information for BeneFIX

• BeneFIX is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein.
• Call your health care provider right away if your bleeding is not controlled after using BeneFIX.
• Allergic reactions may occur with BeneFIX. Call your health care provider or get emergency treatment right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, your lips and gums turning blue, fast heartbeat, facial swelling, faintness, rash or hives.
• Your body can make antibodies, called “inhibitors,” which may interfere with the effectiveness of BeneFIX.
• If you have risk factors for developing blood clots, such as a venous catheter through which BeneFIX is given by continuous infusion, BeneFIX may increase the risk of abnormal blood clots. The safety and efficacy of BeneFIX administration by continuous infusion have not been established.
• Some common side effects of BeneFIX are nausea, injection site reaction, injection site pain, headache, dizziness and rash.

Please see full Prescribing Information for BeneFIX.